Sunshine Biopharma Inc. (SBFM: Quote) announced Tuesday that its parent company Advanomics Corp. has filed a new patent application for Adva-27a.
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells as well as other aggressive cancer cells in vitro. The compound is currently in the IND-Enabling stage of development.
No comments:
Post a Comment